Igenica Appoints Mary Haak-Frendscho CEO
This article was originally published in Scrip
Executive Summary
Igenica, a biopharmaceutical company discovering and developing cancer antibody therapeutics, has named Dr Mary Haak-Frendscho CEO and a member of the board of directors. Dr Haak-Frendscho, who was previously the founding president and CSO of Takeda San Francisco, succeeds Dr David Goeddel, who remains as Igenica's chair.